NASDAQ: ROIV · Life Sciences · 11 alerts · CIK 1635088
Share price
$38.61Close, Nov 16
Market cap
$28B
Shares outstanding
724.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Roivant Sciences Ltd. filings on SEC EDGAR ↗
Roivant Sciences CFO Richard Pulik Sells $12.5M of Stock
Richard Pulik, CFO, sold 300,000 shares of Roivant Sciences Ltd. at $41.20 to $42.03 a share (average $41.58) in 4 transactions, worth $12.5M in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 222,046 (-17.7%).
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.62M of Stock
Eric Venker, President & Immunovant CEO, sold 187,943 shares of Roivant Sciences Ltd. at $40.44 to $41.00 a share (average $40.53) in 2 transactions, worth $7.62M in total on Nov 10, 2026. Shares held after the trade: 811,211 (-3.5%).
Roivant Sciences Ltd. reported 724,561,460 common shares outstanding as of November 3, 2026. The filing includes condensed consolidated financial statements for the three and six months ended September 30, 2026, and highlights risks related to biopharmaceutical product development, capital allocation, and its 'Vant' structure.
Roivant Sciences reported financial results for its second fiscal quarter ended September 30, 2026, highlighted by $31.0 million in net product revenue from the first five weeks of the LISRAYA launch. The company also announced positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in non-infectious uveitis, ending the period with $4.2 billion in cash and marketable securities.
Term
Q2 2026
“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand.”
Matt Gline, CEO of Roivant
“Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options.”
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.26M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.31 a share, worth $7.26M in total on Nov 3, 2026. Shares held after the trade: 999,154 (-16.7%).
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.32M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.59 a share, worth $7.32M in total on Oct 28, 2026. Shares held after the trade: 1,199,154 (-14.3%).
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.02M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $35.09 to $35.42 a share (average $35.11) in 2 transactions, worth $7.02M in total on Oct 20, 2026. Shares held after the trade: 1,399,154 (-1.0%).
Roivant and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). The drug met its primary and all key secondary endpoints in two identical trials, demonstrating a median time to treatment failure of over 48 weeks compared to 12 weeks for placebo, and the company plans to file a supplemental New Drug Application (sNDA) in the first half of 2027.
Roivant Sciences Insider Melissa B. Epperly Sells $641K of Stock
Melissa B. Epperly sold 17,750 shares of Roivant Sciences Ltd. at $36.08 to $36.57 a share (average $36.10) in 2 transactions, worth $641K in total on Oct 1, 2026. Shares held after the trade: 14,954 (-5.7%).
Roivant Sciences President & Immunovant CEO Eric Venker Sells $7.32M of Stock
Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. at $36.62 a share, worth $7.32M in total on Sep 30, 2026. Shares held after the trade: 1,599,154 (-11.1%).
Roivant Sciences Ltd. held its 2026 Annual General Meeting of Shareholders on September 16, 2026, where shareholders approved all three agenda proposals. Key outcomes included the re-election of Daniel Gold and Meghan FitzGerald as Class II directors, the ratification of Ernst & Young LLP as the independent auditor, and the advisory approval of executive compensation.